

BMS halts Hep C drug administration

02 August 2012 | News | By BioSpectrum Bureau

BMS halts Hep C drug administration



Singapore: Bristol-Myers Squibb (BMS) has suspended study drug administration in an ongoing phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken for patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are yet to be known.

With patient safety as the priority, the company is undertaking an immediate assessment of all patients in the study, and following an evaluation of the patient data, will take appropriate actions.